Skip to main content

AJOVY (Teva Pharma Australia Pty Ltd)

Product name
AJOVY
Date registered
Evaluation commenced
Decision date
Approval time
202 working days (255)
Active ingredients
fremanezumab
Registration type
NCE/NBE
Indication

AJOVY (solution for injection) is indicated for the preventive treatment of migraine in adults.

Help us improve the Therapeutic Goods Administration site